Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis.
Anti-HEV seroprevalence
HEV
HIV
Hepatitis E virus
Human immunodeficiency virus
immunocompromised patients
transplantation
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
23
04
2020
revised:
09
09
2020
accepted:
29
09
2020
pubmed:
10
10
2020
medline:
27
5
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
Hepatitis E is an infectious disease of the liver caused by the hepatitis E virus (HEV). Immunocompromised patients present a particular risk group, as chronification of hepatitis E leading to life-threatening cirrhosis occurs when these patients are infected. Therefore, this study aims to estimate and compare the anti-HEV seroprevalence and the rate of HEV RNA positivity in transplant recipients and patients with human immunodeficiency virus (HIV). This systematic review and meta-analysis involved a literature search (PubMed, Scopus; 1,138 studies) including 120 studies from 1996 to 2019, reporting anti-HEV seroprevalence and/or HEV-RNA positivity. Statistical analysis was performed using a linear mixed-effects meta regression model. Anti-HEV seroprevalence in 14 626 transplant recipients ranged from 6% (95% CI: 1.9-17.2) to 29.6% (95% CI: 21.6-39.) in different commercially available assays and did not differ significantly compared to 20 825 HIV positive patients (range: 3.5% (95% CI: 0.9-12.8) - 19.4% (95% CI: 13.5-26.9). In contrast, HEV-RNA positivity rate was significantly higher in transplant recipients than in HIV positive patients (1.2% (95% CI: 0.9-1.6) vs 0.39% (95% CI: 0.2-0.7); P-value = 0.0011). Anti-HEV seroprevalence did not differ significantly between transplant recipients and HIV positive patients. Interestingly, rates of HEV-RNA positivity, indicating ongoing infection, were significantly higher in transplant recipients. These findings demonstrate that transplant patients have an elevated risk of chronic infection in comparison to HIV patients at comparable risk of HEV-exposure.
Sections du résumé
BACKGROUND AND AIMS
Hepatitis E is an infectious disease of the liver caused by the hepatitis E virus (HEV). Immunocompromised patients present a particular risk group, as chronification of hepatitis E leading to life-threatening cirrhosis occurs when these patients are infected. Therefore, this study aims to estimate and compare the anti-HEV seroprevalence and the rate of HEV RNA positivity in transplant recipients and patients with human immunodeficiency virus (HIV).
METHODS
This systematic review and meta-analysis involved a literature search (PubMed, Scopus; 1,138 studies) including 120 studies from 1996 to 2019, reporting anti-HEV seroprevalence and/or HEV-RNA positivity. Statistical analysis was performed using a linear mixed-effects meta regression model.
RESULTS
Anti-HEV seroprevalence in 14 626 transplant recipients ranged from 6% (95% CI: 1.9-17.2) to 29.6% (95% CI: 21.6-39.) in different commercially available assays and did not differ significantly compared to 20 825 HIV positive patients (range: 3.5% (95% CI: 0.9-12.8) - 19.4% (95% CI: 13.5-26.9). In contrast, HEV-RNA positivity rate was significantly higher in transplant recipients than in HIV positive patients (1.2% (95% CI: 0.9-1.6) vs 0.39% (95% CI: 0.2-0.7); P-value = 0.0011).
CONCLUSION
Anti-HEV seroprevalence did not differ significantly between transplant recipients and HIV positive patients. Interestingly, rates of HEV-RNA positivity, indicating ongoing infection, were significantly higher in transplant recipients. These findings demonstrate that transplant patients have an elevated risk of chronic infection in comparison to HIV patients at comparable risk of HEV-exposure.
Substances chimiques
Hepatitis Antibodies
0
Immunoglobulin G
0
RNA, Viral
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
449-455Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Horvatits T, Schulze Zur Wiesch J, Lutgehetmann M, Lohse AW, Pischke S. The Clinical perspective on Hepatitis E. Viruses. 2019;11(7).
Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367(13):1237-1244.
Hartl J, Otto B, Madden RG, et al. Hepatitis E seroprevalence in Europe: A meta-analysis. Viruses. 2016;8(8).
Horvatits T, Ozga AK, Westholter D, et al. Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. Liver Int. 2018;38(11):1951-1964.
Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370(12):1111-1120.
Ingiliz P, Mayr C, Obermeier M, Herbst H, Polywka S, Pischke S. Persisting hepatitis E virus infection leading to liver cirrhosis despite recovery of the immune system in an HIV-infected patient. Clin Res Hepatol Gastroenterol. 2016;40(3):e23-e25.
Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. The New England journal of medicine. 2008;358(8):859-860.
Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140(5):1481-1489.
Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361(10):1025-1027.
Kaba M, Richet H, Ravaux I, et al. Hepatitis E virus infection in patients infected with the human immunodeficiency virus. J Med Virol. 2011;83(10):1704-1716.
Kuniholm MH, Ong E, Hogema BM, et al. Acute and chronic Hepatitis E Virus infection in human immunodeficiency virus-infected U.S. Women. Hepatology. 2016;63(3):712-720.
Carubbi F, Picchi G, Di Bartolomeo S, et al. Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. Medicine (Baltimore). 2019;98(33):e16399-e16399.
Ikeuchi H, Koinuma K, Nakasatomi M, et al. Hepatitis E during tocilizumab therapy in a patient with Rheumatoid Arthritis: Case report and literature review. Case Rep Rheumatol. 2018;2018:6873276-6873276.
van Bijnen STA, Ledeboer M, Martens HA. Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate. Rheumatology. 2016;56(3):497-498.
Alnuaimi K, Lavolé J, Lascoux-Combes C, et al. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine. Hepatology. 2018;67(6):2468-2470.
Ankcorn MJ, Fox TA, Ijaz S, et al. Characterising the risk of Hepatitis E virus infection in haematological malignancies: a UK prospective prevalence study. British Journal of Haematology. 2019;186(1):191-195.
van der Eijk AA, Pas SD, Cornelissen JJ, de Man RA. Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis. 2014;27(4):309-315.
Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(6):1079-1086.
Pischke S, Peron JM, von Wulffen M, et al. Chronic Hepatitis E in rheumatology and internal medicine patients: A retrospective multicenter European cohort study. Viruses. 2019;11(2).
von Felden J, Laurent A, Pischke S, et al. The Burden of Hepatitis E among Patients with Haematological Malignancy: a Retrospective European Cohort Study. J Hepatol. 2019: Epub ahead of print.
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA. 2018;319(4):388-396.
JBI. Joanna Briggs Institute - Critical Appraisal Checklist for Prevalence Studies. http://joannabriggsorg/research/critical-appraisal-toolshtml. 2016.
Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123-128.
Fang SY, Han H. Hepatitis E viral infection in solid organ transplant patients. Curr Opin Organ Transplant. 2017;22(4):351-355.
Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant. 2012;12(11):3128-3133.
Debes JD, Pisano MB, Lotto M, Re V. Hepatitis E virus infection in the HIV-positive patient. J Clin Virol. 2016;80:102-106.
Feldt T, Sarfo FS, Zoufaly A, et al. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. J Clin Virol. 2013;58(1):18-23.
Crum-Cianflone NF, Curry J, Drobeniuc J, et al. Hepatitis E virus infection in HIV-infected persons. Emerg Infect Dis. 2012;18(3):502-506.
Keane F, Gompels M, Bendall R, et al. Hepatitis E virus coinfection in patients with HIV infection. HIV Med. 2012;13(1):83-88.
Shinohara N, Owada T, Tanaka A, Matsubayashi K, Nagai T, Satake M. Hepatitis A virus and hepatitis E virus prevalence relates to Human Immunodeficiency Virus infection in Japanese male blood donors. Microbiol Immunol. 2020.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256-1271.
McPherson S, Elsharkawy AM, Ankcorn M, et al. Summary of the british transplantation society UK guidelines for Hepatitis E and solid organ transplantation. Transplantation. 2018;102(1):15-20.
Liver EAftSot. EASL clinical practice guidelines on Hepatitis E virus infection. J Hepatol 2018;6:1256-1271.
Choi M, Hofmann J, Kohler A, et al. Prevalence and clinical correlates of chronic hepatitis e infection in german renal transplant recipients with elevated liver enzymes. Transplant Direct. 2018;4(2):e341.